Empirical results from this study using the developed BIMSSA reveal an accuracy of 0.967, 0.962, 0.951, and 0.971 for ALL-AML, Lymphoma, MLL, and SRBCT datasets. This evidence concerns the gene KMT2A and acute myeloid leukemia.